Alliances Announces 2021 State of the Science Summit
With a commitment to invest $30 million toward innovative and life-saving research by 2024, the Colorectal Cancer Alliance is taking a nuanced look at colorectal cancer research today to understand where it can have the greatest impact tomorrow.
The 2021 State of the Science Summit, set to meet virtually on October 4, is a last step in the Alliance’s research-field analysis before charting a five-year plan that will come to define its scientific strategy.
The summit will bring together multidisciplinary experts to collaboratively align on priority areas of research innovation and opportunity for colorectal advancements.
“We are looking for research domains where the Alliance can have the largest return on investment, answer questions that matter to patients, and ultimately save the most lives,” said Andrea Goodman, MSW, MPH, the Alliance’s Vice President of Patient Support and Research Strategy. “To do so, we are listening to patients, providers, and experts from every corner of the research community to understand where the greatest needs exist.”
Based on a forthcoming research landscape analysis commissioned by the Alliance, the summit will solicit detailed feedback in these areas, among others:
- Advancing new diagnostics and biomarkers
- Identifying new targets and improving therapies
- Overcoming health disparities and expanding screening
The need for research resulting in improved outcomes for colorectal cancer patients is clear. Despite significant advances in both the treatment and prevention of colorectal cancer, in the U.S. alone, more than 1.3 million people are living with a history of colorectal cancer in 2021. This includes approximately 150,000 new cases and 53,000 deaths this year.
A public report from the summit, which is invite-only, will be available in early November.
Top resources
Be heard this November: The Cancer Promise
Learn about The Cancer Promise initiative and how political candidates can pledge to support cancer research, prevention, and care policies. Make your voice heard this election.
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Alliance supports the Clinical Trials Modernization Act
This bipartisan legislation aims to improve participation in clinical trials by addressing major barriers such as non-medical expenses, trial location accessibility, diverse participation, and financial implications for patients.